Neurochem's tramiprosate gets FDA fast-track status

(Reuters) - The biotechnology company said it planned to meet with the FDA in August to discuss its Phase 3 program as well as to provide an update on North American Phase 3 clinical trials.






Read more at Reuters.com Government Filings News